{
    "2019-12-11": [
        [
            {
                "time": "2018-11-05",
                "original_text": "Top Research Reports for Novartis, AbbVie & Sanofi",
                "features": {
                    "keywords": [
                        "Novartis",
                        "AbbVie",
                        "Sanofi",
                        "research reports"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-03-14",
                "original_text": "Roche's sBLA for Asthma Drug Xolair Accepted by FDA",
                "features": {
                    "keywords": [
                        "Roche",
                        "Xolair",
                        "FDA",
                        "sBLA",
                        "asthma"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-07-22",
                "original_text": "The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint",
                "features": {
                    "keywords": [
                        "Correvio",
                        "FDA",
                        "rejection",
                        "Iterum",
                        "antibiotic",
                        "trial failure"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}